Indirect treatment comparison shows zanubrutinib enhances progression-free survival in relapsed/refractory CLL, suggesting potential benefits over other BTK inhibitors.
This ML-NMR suggests that zanubrutinib offers improved PFS compared to ibrutinib and acalabrutinib in both general and high-risk R/R CLL populations. OS results were uncertain due to limited follow-up.
No takes yet. Share an insight, caveat, or question.
Shadman et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: